&nbsp;

Apr 2024

Drug

AFAtinib

Other Name(s): Giotrif®

Quick Link(s):

Apr 2024

Drug

alectinib

Other Name(s): Alecensaro®

Quick Link(s):

Apr 2024

Drug

midostaurin

Other Name(s): Rydapt®

Quick Link(s):

Jun 2022

Regimen

AXIT

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - For second or third line treatment of advanced renal cell carcinoma, according to clinical criteria

Drugs Used:

aXitinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

AFAT

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

AFAtinib - For first-line monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria

Drugs Used:

AFAtinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

MPT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Exceptional Access Program

thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

alectinib - Treatment of non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

ATRA(IND)

Cancer Type:

Hematologic,

Leukemia - Acute Promyelocytic (APL)

Intent: Palliative, Curative

Funding:

Exceptional Access Program

tretinoin (ATRA)

Drugs Used:

tretinoin (ATRA)

Quick Link(s):

Regimen Monograph

May 2019

Regimen

ATRA(MNT)

Cancer Type:

Hematologic,

Leukemia - Acute Promyelocytic (APL)

Intent: Curative, Palliative

Funding:

Exceptional Access Program

tretinoin (ATRA)

Drugs Used:

tretinoin (ATRA)

Quick Link(s):

Regimen Monograph

May 2019

Regimen

ARSEATRA(CONS LO/INT)

Cancer Type:

Hematologic,

Leukemia - Acute Promyelocytic (APL)

Intent: Curative

Funding:

New Drug Funding Program

Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)

New Drug Funding Program

Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)

Exceptional Access Program

tretinoin (ATRA)

Drugs Used:

tretinoin (ATRA),

arsenic trioxide

Quick Link(s):

Regimen Monograph

Jul 2021

Regimen

ARSEATRA(IND LO/INT)

Cancer Type:

Hematologic,

Leukemia - Acute Promyelocytic (APL)

Intent: Curative

Funding:

New Drug Funding Program

Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)

New Drug Funding Program

Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)

Exceptional Access Program

tretinoin (ATRA)

Drugs Used:

tretinoin (ATRA),

arsenic trioxide